Abstract 162P
Background
Hepatocellular carcinoma (HCC) after curative treatment has an estimated 5-year recurrence rate up to 70% [1]. Intrahepatic recurrence follows a bimodal pattern, with early recurrence occurring within 2 years and late recurrence occurring at 5 years [2]. It is unknown whether the bimodal recurrence pattern remains in the era of antivirals, which could reduce late recurrence. In this study, we provide an update of the characteristics of recurrence pattern.
Methods
Eligible patients who had received surgery or RFA for HCC from Oct 2000 to Jul 2017 were recruited at the Prince of Wales Hospital, Hong Kong. Patients’ and tumors’ characteristics were collected. Pattern of recurrence was classified by the occurrence of intrahepatic (local) recurrence or presence of distant metastasis (DM). Time-to-recurrence (TTR) and overall survival (OS) measure the time between the diagnosis of HCC to the time of first recurrence and death due to any cause respectively. Both TTR and OS were assessed using Kaplan-Meier Method. Prognostic factors for LR and DM were assessed using univariate and multivariate Cox Proportional Hazards Model.
Results
1082 patients were recruited. There were 908 (84%) males. 834 (77%) patients had HBV and 76 (7%) patients had HCV. 831 (77%) patients had BCLC stage 0/A and 243 (23%) patients had BCLC stage B/C HCC. 997 (92%) and 676 (63%) patients had Child-Pugh A and ALBI grade 1 liver function respectively. Median tumor size was 3.5cm. 834 (77%) patients had solitary HCC, and 99 (9%), 21 (2%) and 126 (12%) patients had 2, 3 and ≥3 HCCs respectively. 863 (80%) patients received surgery and 219 (20%) patients received RFA. The TTR for both LR and DM peaked at 9 to 12 months then dropped progressively. The bimodal recurrence pattern was not apparent. In patients who developed recurrence, median OS was longest in those with LR only at 64.8 months, versus shortest in those who developed DM first then LR at 13.3 months.
Conclusions
In the era of antivirals, the bimodal recurrence pattern is not observed with a marked reduction of late recurrence. The pattern of recurrence influences the prognosis: patients with LR have significantly better OS than DM. These findings are important for future research on adjuvant and salvage treatment for recurrent HCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
L.L. Chan: Other, Personal, Other, Travel Grant: Roche. K. Mok: Other, Personal, Other, Travel Grant: AstraZeneca, Eisai. S.L. Chan: Financial Interests, Personal, Advisory Board: Eisai, AstraZeneca, MSD, BMS, Roche; Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, Eisai, Roche, Ipsen, BMS; Financial Interests, Personal, Research Grant: Eisai, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract